LIVN · Insider Trading
LivaNova PLC Ordinary Shares
Every open-market purchase and sale reported by LIVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Anne M. Liddy | Chief Legal Officer | A | +6,291 deriv. | — |
| 2026-09-14 | Francesco Bianchi | Director | Sell | −3,500 | −$273.03K |
| 2026-09-08 | Brooke Story | Director | Sell | −2,300 | −$187.27K |
| 2026-09-02 | Francesco Bianchi | Director | Sell | −1,650 | −$131.54K |
| 2026-08-13 | Ahmet Tezel | Chief Innovation Officer | MIXED | — | −$319.25K |
| 2026-06-17 | Todd C Schermerhorn | Director | MIXED | +3,556 | −$38.73K |
| 2026-06-17 | James Christopher Barry | Director | MIXED | +3,556 | −$38.73K |
| 2026-06-17 | Francesco Bianchi | Director | MIXED | +2,356 | −$134.96K |
| 2026-06-17 | Seng Stacy Enxing | Director | MIXED | +3,556 | −$38.73K |
| 2026-06-17 | Ahmet Tezel | Chief Innovation Officer | MIXED | +1,933 | −$82.25K |
| 2026-06-17 | Peter M Wilver | Director | MIXED | +3,556 | −$38.73K |
| 2026-06-17 | Jette Nygaard-Andersen | Director | A | +2,383 deriv. | — |
| 2026-06-17 | William A Kozy | Director | MIXED | +4,999 | −$54.36K |
| 2026-06-17 | Susan M Podlogar | Director | MIXED | +3,556 | −$38.73K |
| 2026-06-17 | Donald Zurbay | Director | MIXED | +2,252 | −$24.55K |
| 2026-06-17 | Brooke Story | Director | MIXED | +3,556 | −$38.73K |
| 2026-05-27 | Francesco Bianchi | Director | Sell | −1,800 | −$136.35K |
| 2026-04-01 | Natalia Kozmina | Chief Human Resources Officer | MIXED | +5,015 | −$84.18K |
| 2026-04-01 | Stephanie Bolton | President, Global Epilepsy | MIXED | +9,438 | −$513.26K |
| 2026-04-01 | Vladimir Makatsaria | Chief Executive Officer | MIXED | +9,883 | −$683.71K |
| 2026-04-01 | Alex Shvartsburg | Chief Financial Officer | MIXED | +17,967 | −$788.42K |
| 2026-04-01 | Franco Poletti | President, Cardiopulmonary | MIXED | +1,814 | −$83.94K |
| 2026-04-01 | Ahmet Tezel | Chief Innovation Officer | MIXED | +2,222 | −$72.67K |
| 2026-03-13 | Franco Poletti | President, Cardiopulmonary | MIXED | +91 | −$4.31K |
| 2025-12-17 | Michael Damon Hutchinson | SVP, CLO and Company Secretary | MIXED | +1,132 | −$70.75K |
| 2025-12-17 | Susan M Podlogar | Director | MIXED | +2,086 | −$16.96K |
| 2025-12-17 | Franco Poletti | President, Cardiopulmonary | MIXED | +551 | −$26.23K |
| 2025-11-19 | Brooke Story | Director | Sell | −250 | −$13.48K |
| 2025-09-17 | Franco Poletti | President, Cardiopulmonary | MIXED | +366 | −$15.35K |
| 2025-09-17 | Donald Zurbay | Director | A | +2,560 deriv. | — |
| 2025-08-27 | Francesco Bianchi | Director | Sell | −1,500 | −$84.75K |
| 2025-06-17 | Susan M Podlogar | Director | A | +4,042 deriv. | — |
| 2025-06-17 | Ahmet Tezel | Chief Innovation Officer | MIXED | +1,935 | −$47.22K |
| 2025-06-17 | Peter M Wilver | Director | MIXED | +3,006 | −$18.76K |
| 2025-06-17 | Seng Stacy Enxing | Director | MIXED | +3,006 | −$18.76K |
| 2025-06-17 | Brooke Story | Director | MIXED | +3,006 | −$18.76K |
| 2025-06-17 | James Christopher Barry | Director | MIXED | +3,006 | −$18.76K |
| 2025-06-17 | William A Kozy | Director | MIXED | +4,259 | −$26.59K |
| 2025-06-17 | Todd C Schermerhorn | Director | MIXED | +3,006 | −$18.76K |
| 2025-06-17 | Francesco Bianchi | Director | MIXED | +3,006 | −$18.76K |
| 2025-06-17 | Sharon O'Kane | Director | MIXED | +1,810 | −$73.49K |
| 2025-04-01 | Franco Poletti | President, Cardiopulmonary | MIXED | +715 | −$21.21K |
| 2025-04-01 | Natalia Kozmina | Chief Human Resources Officer | A | +45,927 deriv. | — |
| 2025-04-01 | Alex Shvartsburg | Chief Financial Officer | MIXED | +7,567 | −$137.58K |
| 2025-04-01 | Michael Damon Hutchinson | Chief Legal Officer | MIXED | +1,910 | −$39.91K |
| 2025-04-01 | William A Kozy | Director | MIXED | +846 | −$7.36K |
| 2025-04-01 | Vladimir Makatsaria | Chief Executive Officer | MIXED | +4,284 | −$197.45K |
| 2025-04-01 | Stephanie Bolton | President, Global Epilepsy | MIXED | +3,189 | −$110.93K |
| 2025-04-01 | Ahmet Tezel | Chief Innovation Officer | A | +53,044 deriv. | — |
| 2024-12-17 | Susan M Podlogar | Director | A | +2,355 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Alex Shvartsburg | Chief Financial Officer | 44,647 | $4.13M |
| William A Kozy | Director | 38,248 | $3.54M |
| Stephanie Bolton | President, Global Epilepsy | 30,566 | $2.83M |
| Vladimir Makatsaria | Chief Executive Officer | 25,326 | $2.34M |
| Seng Stacy Enxing | Director | 15,793 | $1.46M |
| Todd C Schermerhorn | Director | 12,619 | $1.17M |
| Franco Poletti | President, Cardiopulmonary | 12,344 | $1.14M |
| Sharon O'Kane | Director | 11,304 | $1.05M |
| Peter M Wilver | Director | 10,294 | $953.12K |
| James Christopher Barry | Director | 8,404 | $778.13K |
| Brooke Story | Director | 7,488 | $693.31K |
| Michael Damon Hutchinson | SVP, CLO and Company Secretary | 6,798 | $629.43K |
| Ahmet Tezel | Chief Innovation Officer | 6,090 | $563.87K |
| Susan M Podlogar | Director | 5,642 | $522.39K |
| Natalia Kozmina | Chief Human Resources Officer | 5,015 | $464.34K |
| Francesco Bianchi | Director | 4,434 | $410.54K |
| Donald Zurbay | Director | 2,252 | $208.51K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LIVN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.